🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

SUrveillance of PREMalignant Stomach - Individualized Endoscopic Follow-up

RecruitingNAAges 45 Years - anyAllInstituto Portugues de Oncologia, Francisco Genti…
NCT04613570 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Introduction: Gastric atrophy and intestinal metaplasia are the principal precursors for gastric cancer and, therefore, are considered gastric premalignant conditions. Although current guidelines recommend surveillance of individuals with these conditions, the best method for its identification and staging (histological vs endoscopy) and the best time schedule for follow-up are still controversial. Aims: To describe for the first-time patients with premalignant conditions both clinically (familial history), histologically (OLGA/OLGIM; complete/incomplete metaplasia) and endoscopically (EGGIM) using validated scales and to describe evolution of these parameters through time. To estimate prospectively the gastric cancer risk according to EGGIM stages. To define the best endoscopic surveillance follow-up for the several stages considering clinical, histological and endoscopic factors. Meth

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients scheduled for upper GI endoscopy with indication for gastric biopsies, including those with known gastric pathology (e.g. auto-immune gastritis) or premalignant conditions (e.g patients under surveillance because of atrophic gastritis); * Age above 45 years old Exclusion Criteria: * History of previous gastrectomy; * History of endoscopic resection of neoplastic lesion * History of previous gastric dysplasia (even with no detectable lesion) * Hereditary syndromes that increase gastric cancer risk (familial adenomatous polyposis; Lynch syndrome) * Serious comorbidities (ASA 3 or more) * Medication with anticoagulants
💊

What it tests

  • Upper gastrointestinal endoscopy
📍

Where

1 site
IPO-Porto
Porto, Portugal
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy